Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease

• Autores: Albareda, María Cecilia; Laucella, Susana Adriana
• Año de publicación: 2015
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Memorias do instituto Oswaldo Cruz 2015;110(3):414-421
• Materia: Linfocitos T; Enfermedad de Chagas; Trypanosoma cruzi; Quimioterapia
• Institución: Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"

Fil: Albareda, María Cecilia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
Fil: Laucella, Susana Adriana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
The aim of this review is to describe the contributions of the knowledge of T-cell responses to the understanding of the physiopathology and the responsiveness to etiological treatment during the chronic phase of Chagas disease. T-helper (Th)1 and interleukin (IL)-10 Trypanosoma cruzi-specific T-cells have been linked to the asymptomatic phase or to severe clinical forms of the disease, respectively or vice versa, depending on the T. cruzi antigen source, the patient's location and the performed immunological assays. Parasite-specific T-cell responses are modulated after benznidazole (BZ) treatment in chronically T. cruzi-infected subjects in association with a significant decrease in T. cruzi-specific antibodies. Accumulating evidence has indicated that treatment efficacy during experimental infection with T. cruzi results from the combined action of BZ and the activation of appropriate immune responses in the host. However, strong support of this interaction in T. cruzi-infected humans remains lacking. Overall, the quality of T-cell responses might be a key factor in not only disease evolution, but also chemotherapy responsiveness. Immunological parameters are potential indicators of treatment response regardless of achievement of cure. Providing tools to monitor and provide early predictions of treatment success will allow the development of new therapeutic options.